Development and Structural Modification of BACE1 Inhibitors
AbstractAlzheimer’s disease (AD) is a progressive neurodegenerative disorder which usually occurs in the elderly. The accumulation of β-amyloid and the formation of neurofibrillary tangles are considered as the main pathogenies of AD. Research suggests that β-secretase 1 (BACE1) plays an important role in the formation of β-amyloid. Discovery of new BACE1 inhibitors has become a significant method to slow down the progression of AD or even cure this kind of disease. This review summarizes the different types and the structural modification of these new BACE1 inhibitors. View Full-Text
Share & Cite This Article
Gu, T.; Wu, W.-Y.; Dong, Z.-X.; Yu, S.-P.; Sun, Y.; Zhong, Y.; Lu, Y.-T.; Li, N.-G. Development and Structural Modification of BACE1 Inhibitors. Molecules 2017, 22, 4.
Gu T, Wu W-Y, Dong Z-X, Yu S-P, Sun Y, Zhong Y, Lu Y-T, Li N-G. Development and Structural Modification of BACE1 Inhibitors. Molecules. 2017; 22(1):4.Chicago/Turabian Style
Gu, Ting; Wu, Wen-Yu; Dong, Ze-Xi; Yu, Shao-Peng; Sun, Ying; Zhong, Yue; Lu, Yu-Ting; Li, Nian-Guang. 2017. "Development and Structural Modification of BACE1 Inhibitors." Molecules 22, no. 1: 4.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.